CURRENT POSSIBILITIES FOR TREATING ATRIAL FIBRILLATION

Download full text PDF
Issue: 
9
Year: 
2016

Professor S. Kanorsky, MD Kuban State Medical University, Krasnodar

The paper considers possibilities for enhancing the efficiency of antiarrhythmic drug therapy for atrial fibrillation, as well as the latest advances in its non-drug therapy, particularly catheter ablation in the left atrium and lifestyle modification in patients.

Keywords: 
atrial fibrillation
oral anticoagulants
closure of the left atrial appendage
migraine
antiarrhythmic drugs
catheter ablation



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Chugh S., Havmoeller R., Narayanan K. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study // Circulation. – 2014; 129: 837–47.
  2. Mozaffarian D., Benjamin E., Go A. et al. American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Executive Summary: Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association // Circulation. – 2016; 133: 447–54.
  3. Andrade J., Khairy P., Dobrev D. et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms // Circ. Res. – 2014; 114: 1453–68.
  4. Kochhäuser S., Joza J., Essebag V. et al. The Impact of Duration of Atrial Fibrillation Recurrences on Measures of Health-Related Quality of Life and Symptoms // Pacing Clin. Electrophysiol. – 2016; 39: 166–72.
  5. O'Neal W., Qureshi W., Zhang Z. et al. Bidirectional association between atrial fibrillation and congestive heart failure in the elderly // J. Cardiovasc. Med. (Hagerstown). – 2016; 17: 181–6.
  6. Chamberlain A., Gersh B., Alonso A. et al. Decade-long trends in atrial fibrillation incidence and survival: a community study // Am. J. Med. – 2015; 128: 260–7.
  7. Heijman J., Voigt N., Nattel S. et al. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression // Circ. Res. – 2014; 114: 1483–99.
  8. Heijman J., Voigt N., Dobrev D. New directions in antiarrhythmic drug therapy for atrial fibrillation // Future Cardiol. – 2013; 9: 71–88.
  9. Heijman J., Algalarrondo V., Voigt N. et al. The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis // Cardiovasc. Res. – 2016; 109: 467–79.
  10. O’Neal W., Venkatesh S., Broughton S. et al. Biomarkers and the prediction of atrial fibrillation: state of the art // Vasc. Health Risk Manag. – 2016; 12: 297–303.
  11. Van Gelder I., Hobbelt A., Marcos E. et al. Tailored treatment strategies: a new approach for modern management of atrial fibrillation // J. Intern. Med. – 2016; 279: 457–66.
  12. Filgueiras-Rama D., Jalife J. Structural and functional bases of cardiac fibrillation. Differences and similarities between atria and ventricles // JACC Clin. Electrophysiol. – 2016; 2: 1–3.
  13. Lau D., Schotten U., Mahajan R. et al. Novel mechanisms in the pathogenesis of atrial fibrillation: practical applications // Eur. Heart J. – 2016; 37: 1573–81.
  14. Ganesan A., Chew D., Hartshorne T. et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis // Eur. Heart J. – 2016; 37: 1591–602.
  15. Kanorskij S.G. Antiaritmicheskaja terapija u bol'nyh s paroksiz mal'noj i persistirujuschej formami fibrilljatsii predserdij: opredele-nie dostizhimoj tseli i otsenka imejuschihsja sredstv // Kardiologija. – 2014; 2: 70–4.
  16. Camm A., Lip G., De Caterina R. et al. ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association // Eur. Heart J. – 2012; 33: 2719–47.
  17. January C., Wann L., Alpert J. et al. ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society // Circulation. – 2014; 130: e199–e267.
  18. Tereshchenko L., Henrikson C., Cigarroa J. et al. Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis // J. Am. Heart Assoc. – 2016; 5: 5.
  19. Savelieva I., Camm A. Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation // Clin. Cardiol. – 2014; 37: 32–47.
  20. Gonzalez Quesada C., Giugliano R. Selecting an oral anticoagulant for patients with nonvalvular atrial fibrillation // J. Thromb. Thrombolysis. – 2015; 39: 129–38.
  21. Heidbuchel H., Verhamme P., Alings M. et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary // Eur. Heart J. – 2016 Jun 9. [Epub ahead of print]
  22. Reddy V., Sievert H., Halperin J. et al. PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial // JAMA. – 2014; 312: 1988–98.
  23. Holmes D. Jr., Kar S., Price M. et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial // J. Am. Coll. Cardiol. – 2014; 64: 1–12.
  24. Ruff C., Giugliano R., Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials // Lancet. – 2014; 383: 955–62.
  25. Marijon E., Le Heuzey J., Connolly S. et al. RE-LY Investigators. Causes of . death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study // Circulation. – 2013; 128: 2192–201.
  26. Van Gelder I., Groenveld H., Crijns H. et al. RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation // N. Engl. J. Med. – 2010; 362: 1363–73.
  27. Giner-Soriano M., Roso-Llorach A., Vedia Urgell C. et al. Drug Therapy for Rate and Rhythm Control in Nonvalvular Atrial Fibrillation: A Cross-sectional Study With Electronic Health Records in a Primary Care Cohort // Clin. Ther. – 2016; 38: 863–73.
  28. Ponikowski P., Voors A., Anker S. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC // Eur. Heart J. – 2016; 37: 2129–200.
  29. Kotecha D., Holmes J., Krum H. et al. Beta-Blockers in Heart Failure Collaborative Group. Efficacy of blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis // Lancet. – 2014; 384: 2235–43.
  30. Mareev Y., Cleland J. Should -blockers be used in patients with heart failure and atrial fibrillation? // Clin. Ther. – 2015; 37: 2215–24.
  31. Halsey C., Chugh A. Rate Versus Rhythm Control for Atrial Fibrillation // Heart Fail Clin. – 2016; 12: 193–203.
  32. Wyse D., Waldo A., DiMarco J. et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation // N. Engl. J. Med. – 2002; 347: 1825–33.
  33. Van Gelder I., Hagens V., Bosker H. et al. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation // N. Engl. J. Med. – 2002; 347: 1834–40.
  34. Rienstra M., Van Gelder I., Hagens V. et al. Mending the rhythm does not improve prognosis in patients with persistent atrial fibrillation: a subanalysis of the RACE study // Eur. Heart J. – 2006; 27: 357–64.
  35. Van Gelder I., Haegeli L., Brandes A. et al. Rationale and current perspective for early rhythm control therapy in atrial fibrillation // Europace. – 2011; 13: 1517–25.
  36. Comtois P., Kneller J., Nattel S. Of circles and spirals: bridging the gap between the leading circle and spiral wave concepts of cardiac reentry // Europace. – 2005; 7 (Suppl. 2): 10–20.
  37. Aguilar M., Nattel S. The Past, Present, and Potential Future of Sodium Channel Block as an Atrial Fibrillation Suppressing Strategy // J. Cardiovasc. Pharmacol. – 2015; 66: 432–40.
  38. Andrade J., Roy D., Wyse D. et al. ECG Features Associated With Adverse Cardiovascular Outcomes in Patients With Atrial Fibrillation: A Combined AFFIRM and AF-CHF Analysis // J. Cardiovasc. Electrophysiol. – 2016; 27: 404–13.
  39. Ofitsial'naja publikatsija patenta RF №2513580 http://www.freepatent. ru/patents/2513580
  40. Vamos M., Hohnloser S. Amiodarone and dronedarone: An update // Trends Cardiovasc. Med. – 2016 Apr 4. [Epub ahead of print]
  41. McCauley M., Vallabhajosyula S., Darbar D. Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients Card // Electrophysiol. Clin. – 2016; 8: 481–93.
  42. Jackson N., Atar D., Borentain M., et al. Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology // Eur. Heart J. – 2016; 37: 747–54.
  43. Erlih A.D. Izuchenie dokazatel'noj bazy ispol'zovanija lappakoniti na gidrobromida u patsientov s fibrilljatsiej predserdij // Kardiologija. – 2016; 3: 48–53.
  44. Kanorskij S.G. Sovremennaja medikamentoznaja terapija fibrilljatsii predserdij: vybor taktiki, antiaritmicheskih preparatov i shem lechenija // Kardiologija. – 2012; 9: 58–63.
  45. Aguilar M., Xiong F., Qi X. et al. Potassium Channel Blockade Enhances Atrial Fibrillation-Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade // Circulation. – 2015; 132: 2203–11.
  46. Reiffel J., Camm A., Belardinelli L. et al. The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism // Circ. Arrhythm. Electrophysiol. – 2015; 8: 1048–56
  47. Capucci A., Piangerelli L., Ricciotti J. et al. Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation // Europace. – 2016 Feb 17. [Epub. ahead of print].
  48. Nishida K., Datino T., Macle L. et al. Atrial fibrillation ablation: translating basic mechanistic insights to the patient // J. Am. Coll. Cardiol. – 2014; 64: 823–31.
  49. Nattel S. Paroxysmal atrial fibrillation and pulmonary veins: relationships between clinical forms and automatic versus re-entrant mechanisms // Can. J. Cardiol. – 2013; 29: 1147–9.
  50. Verma A., Jiang C., Betts T. et al. Approaches to catheter ablation for persistent atrial fibrillation // N. Engl. J. Med. – 2015; 372: 1812–22.
  51. Mohanty S., Gianni C., Mohanty P. et al. Impact of Rotor Ablation in Nonparoxysmal Atrial Fibrillation Patients: Results From the Randomized OASIS Trial // J. Am. Coll. Cardiol. – 2016; 68: 274–82.
  52. Shi L., Heng R., Liu S. et al. Effect of catheter ablation versus antiarrhythmic drugs on atrial fibrillation: A meta-analysis of randomized controlled trials // Exp. Ther. Med. – 2015; 10: 816–22.
  53. Di Biase L., Mohanty P., Mohanty S. et al. Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial // Circulation. – 2016; 133: 1637–44.
  54. Friberg L., Tabrizi F., Englund A. Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries // Eur. Heart J. – 2016 Mar 16. [Epub. ahead of print].
  55. Kuck K., Brugada J., F55. ürnkranz A. et al. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation // N. Engl. J. Med. – 2016; 374: 2235–45.
  56. Kuck K., Fürnkranz A., Chun K. et al. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial // Eur. Heart J. – 2016 Jul 5. [Epub ahead of print]
  57. Maurer T., Lundqvist C., Tilz R. et al. What have we learned of ablation procedures for atrial fibrillation? // J. Intern. Med. – 2016; 279: 439–48.
  58. Members of the Sicilian Gambit. The search for novel antiarrhythmic strategies. Sicilian Gambit // Eur. Heart J. – 1998; 19: 1178–96.
  59. Pathak R., Middeldorp M., Meredith M. et al. Long-Term Effect of Goal- Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY) // J. Am. Coll. Cardiol. – 2015; 65: 2159–69.
  60. Savelieva I., Kakouros N., Kourliouros A. et al. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention // Europace. – 2011; 13: 610–25.
  61. Goette A., Sch61. ön N., Kirchhof P. et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial // Circ. Arrhythm. Electrophysiol. – 2012; 5: 43–51.
  62. Alings M., Smit M., Moes M. et al. Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study // Neth. Heart J. – 2013; 21: 354–63.
  63. Sandhu R., Ezekowitz J., Andersson U. et al. The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial // Eur. Heart J. – 2016 Apr 12. [Epub. ahead of print].
  64. Huang H., Darbar D. Genotype influence in responses to therapy for atrial fibrillation // Expert Rev. Cardiovasc. Ther. – 2016 Jul 15 [Epub. ahead of print].
  65. Roberts J., Dewland T., Glidden D. et al. Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation // Am. Heart J. – 2016; 175: 9–17.
  66. Kirchhof P., Breithardt G., Bax J. et al. A roadmap to improve the quality of 66. atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network / European Heart Rhythm Association consensus conference // Europace. – 2016; 18: 37–50.`